Hong Kong Stock Movement: SANAI HEALTH GP plummets 15.52%, active capital flow attracts market attention

Hong Kong Stock Movement SANAI HEALTH GP, down 15.52%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Stocks Ranked High in Industry Transaction Volume Stone Pharmaceutical Group up 0.80%. Based on recent key news: On December 8, Stone Pharmaceutical Group announced that the second marketing authorization application for its subsidiary's developed Semaglutide injection has been accepted by the National Medical Products Administration of China. This product is used for long-term weight management in overweight/obese adults, and clinical trial results show significant advantages in weight loss, blood sugar reduction, and cardiovascular protection, driving the stock price up. Source: Zhitong Finance, Jinshi Data On December 8, Stone Pharmaceutical Group's SYH2069 injection received approval from the U.S. FDA to conduct clinical trials in the United States. This product offers more sustained weight loss effects and is expected to become a new generation therapy, further boosting market confidence. Source: Economic Information Daily On December 9, Stone Pharmaceutical Group's stock price rose 2.4%, marking the largest single-day increase since November 25. The market acceptance of the company's products and the success of clinical trials have driven positive stock performance. Source: Jinshi Data The pharmaceutical industry is active in innovative drug research and development, with high market attention. China Biologic Products Holdings up 1.33%. Based on recent key news: On December 9, the 2025 version of the basic medical insurance catalog and the first commercial insurance catalog were released, supporting innovation, and it is expected that the CXO industry will see performance recovery in the second half of the year. The core innovative products of China Biologic Products have been included in the medical insurance, driving the stock price up. Source: Zhitong Finance On December 9, CMB International recommended buying China Biologic Products, believing that the commercial insurance catalog will open the way for the expansion of commercial medical insurance in China, enhancing market confidence. Source: Zhitong Finance The CXO industry is expected to welcome performance recovery. Hansoh Pharmaceutical up 0.05%. Based on recent key news: On December 8, Hansoh Pharmaceutical's innovative drug Amelior has successfully added two new indications to the 2025 National Medical Insurance Catalog. This move will expand the market coverage of the drug and enhance the company's revenue expectations, driving the stock price up. Source: Zhitong Finance On December 8, the renewal of all indications for Saint-Roche and Hengmu has been included in the 2025 National Medical Insurance Catalog. The renewal ensures the market stability of these drugs, enhances investor confidence, and supports the stock price rise. Source: Economic Information Daily On December 8, other innovative drugs of the group continue to be within the agreement period of the National Medical Insurance Catalog. The continuation of the agreement provides assurance for the company's future revenue growth, further boosting the stock price. Source: Zhitong Finance The pharmaceutical industry is supported by policies, and market confidence is enhanced. Stocks Ranked High in Industry Market Capitalization Hengrui Medicine up 2.48%. Based on recent key news: On December 8, multiple products of Hengrui Medicine were included in the National Medical Insurance Catalog, driving the stock price up. The company's announcement shows that products such as Rituximab injection have been included in the medical insurance catalog for the first time, which is expected to promote sales growth On December 7th, the innovative drug sector performed well overall, with Heng Rui Medicine benefiting from policy support. The success rate of national medical insurance negotiations reached a new high, and the commercial insurance catalog was released, promoting the development of innovative drugs. On December 9th, CMB International gave a leading rating to the pharmaceutical industry, with Heng Rui Medicine being favored. More new drugs entering the medical insurance catalog will help improve clinical medication levels and research and development return rates. The valuation of the innovative drug sector has not yet fully reflected the growth potential